Insider Buying: Agile Therapeutics Inc (NASDAQ:AGRX) CEO Purchases 20,000 Shares of Stock

Agile Therapeutics Inc (NASDAQ:AGRX) CEO Alfred Altomari purchased 20,000 shares of the stock in a transaction dated Monday, June 10th. The stock was acquired at an average price of $1.27 per share, for a total transaction of $25,400.00. Following the completion of the transaction, the chief executive officer now directly owns 258,568 shares of the company’s stock, valued at $328,381.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Alfred Altomari also recently made the following trade(s):

  • On Monday, March 25th, Alfred Altomari purchased 25,000 shares of Agile Therapeutics stock. The stock was acquired at an average price of $1.54 per share, for a total transaction of $38,500.00.

NASDAQ AGRX traded up $0.06 during mid-day trading on Tuesday, reaching $1.33. 171,292 shares of the stock were exchanged, compared to its average volume of 404,681. Agile Therapeutics Inc has a 1-year low of $0.23 and a 1-year high of $1.70. The firm has a market cap of $56.86 million, a P/E ratio of -2.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.91 and a current ratio of 8.91.



Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). As a group, equities analysts predict that Agile Therapeutics Inc will post -0.43 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after acquiring an additional 18,038 shares during the last quarter. Geode Capital Management LLC boosted its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 44,639 shares during the last quarter. Acadian Asset Management LLC boosted its position in Agile Therapeutics by 260.7% during the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after acquiring an additional 226,255 shares during the last quarter. Advisor Group Inc. boosted its position in Agile Therapeutics by 716.7% during the first quarter. Advisor Group Inc. now owns 147,000 shares of the specialty pharmaceutical company’s stock worth $222,000 after acquiring an additional 129,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Agile Therapeutics by 10.0% during the first quarter. Renaissance Technologies LLC now owns 2,133,777 shares of the specialty pharmaceutical company’s stock worth $3,222,000 after acquiring an additional 193,100 shares during the last quarter. Hedge funds and other institutional investors own 42.38% of the company’s stock.

Several analysts have recently commented on AGRX shares. Maxim Group reiterated a “buy” rating and issued a $3.00 price target on shares of Agile Therapeutics in a research report on Monday, February 11th. Janney Montgomery Scott started coverage on shares of Agile Therapeutics in a research report on Friday, April 12th. They issued a “buy” rating and a $4.00 price target on the stock. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 11th. Finally, Oppenheimer began coverage on shares of Agile Therapeutics in a research report on Thursday, June 6th. They issued an “outperform” rating and a $5.00 price target on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Agile Therapeutics has a consensus rating of “Buy” and a consensus price target of $4.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/06/11/insider-buying-agile-therapeutics-inc-nasdaqagrx-ceo-purchases-20000-shares-of-stock.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Read More: Price-Sales Ratio

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.